RE:RE:RE:Theranostics I'm being critical of Jfm here not thtx, just so you know. The company aren't doing this work and it doesn't particularly bother me that they aren't. If they start doing this work I'll take an interest. I don't think the company are set up to do this work but that might not matter. In response to a Q about companion diagnostics/screening tools Christian said they were contracting this work out to some expert assay developers. Maybe those guys are experts in radionuclides, maybe not, likely that's not the work they are contracted to do. Maybe it doesn't matter what is likely.
scarlet1967 wrote: I am starting to think your skepticism lies every where in case of THTX, I believe if they can convince you, they can convince anyone. Maybe they should start having practice sessions with you first before trying to strike deals or promote their programs:)....
qwerty22 wrote: It's a perfect example. Looks like this spun out of Case Western bioengineering department, think of Cleveland Clinic if you want references. This guy is the brains behind it.
https://engineering.case.edu/profiles/zxl125
He's been publishing for 20 years on the subject. Everything says this is a company with deep roots in the subject. No doubt surrounded by all the necessary infrastructure. For me it's not a tech you pull out of a hat when you are renting a couple of lab benches in UQAM. That's not intended to be derogatory towards thtx just a likely description of their reality.
I'm not against the idea that it would be a useful tool but is it at all practical to expect thtx to move into this space given their history and circumstances? That's where my scepticism lies.
Lee430 wrote: Molecular-targeted liquid radiation, is this simular to what jfm1330 has been refering to that Thera could use with the peptide or a completly different new therapy?
https://www.dailybulletin.com/2021/07/24/new-hope-in-the-fight-against-prostate-cancer-we-can-win-this-war/